From: Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
Center no. | Ethics Committee or Institutional Review Board | Department/Organization | City, State/Province, Postal Code Country |
---|---|---|---|
501 | Mayo Clinical Institutional Review Boards | Rochester, MN 55905 | |
502 | The University of Texas/MD Anderson Cancer Center | Office of Protocol Research | Houston, TX 77030 |
503 | UCLA OHRPP | Office of Human Research Protection Program | Los Angeles, CA 90095 |
504 | Dana Farber Cancer Institute | Office for Human Research Studies | Boston, MA 02215 |
505 | Northwestern University | Office for the Protection of Research Subjects | Chicago, IL 60611 |
506 | WIRB (Western Institutional Review Board) | Olympia, WA 98508 | |
511 | Rush University Medical Center | Research & Clinical Trials Administration Office | Chicago, IL 60612 |
512 | MD Anderson Cancer Center/Orlando | Office of Protocol Research | Orlando, FL 32828 |
513 | Wayne State University | Human Investigation Committee | Detroit, MI 48201 |
514 | Quorum Review IRB | Seattle, WA 98101 | |
515 | Medical College of Wisconsin | Institutional Review Board | Milwaukee, WI 53226 |
516 | WIRB (Western Institutional Review Board) | Olympia, WA 98101 | |
517 | Duke University | Duke University Health System IRB | Durham, NC |
519 | Washington University | Human Research Protection Office | St. Louis, MO 63110 |
521 | MedStar Health Research Institute—Georgetown University | Washington, DC 20057 | |
522 | Emory University | IRB | Atlanta, GA 30322 |
523 | Weill Cornell Medical College | Human Research Protection Services | New York, NY 10065 |
524 | IUPUI/Clarian Institutional Review Board | Indianapolis, IN | |
525 | Oregon Health & Science University | Research Integrity Office | Portland, OR 97239 |